Cleveland Clinic Taussig Cancer Institute
F

Management of Relapsed/Refractory Multiple Myeloma

By Cleveland Clinic Taussig Cancer Institute FEATURING Faiz Anwer
February 26, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

19:14
Bristol Myers Squibb Hematology

Study Results of a Treatment Option for AML Patients

Feat. J. Mccloskey, T. Leblanc

Featured Video

15:50
Seagen

Efficacy and Safety Data of a First Line Treatment Option in Patient…

Feat. A. Forman

Related Content

AUTOPLAY
09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and M…

15:31
Parameswaran Hari

Refractory and Relapsing Myeloma - When to Treat and Options Availab…

15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myel…

19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Mult…

18:44
City of Hope

The Promise of Immunotherapy and Newer Agents in Multiple Myeloma

Feat. A. Krishnan
06:23
Parameswaran Hari

Treating Refractory & Relapsing Myeloma: Current Trends and Reco…

15:10
Krina Patel

Developing CAR T-cells in Multiple Myeloma

11:51
Memorial Sloan Kettering Cancer Center

Aiming for Minimal Residual Disease Negative Status in all Myeloma P…

Feat. O. Landgren
05:24
Indy Hematology Review

Therapy for Relapsed Multiple Myeloma

Feat. K. Anderson
12:32
Indy Hematology Review

What's New in Immunotherapy and Genomics in Multiple Myeloma?

Feat. K. Anderson
17:47
Dana-Farber Cancer Institute

Relapse Refractory Myeloma and Novel Treatments

Feat. N. S. Raje
15:02
Krina Patel

Clinical Trials in Myeloma in 2018

16:59
Nina Shah

The Future of CAR T Therapies in Myeloma in 2018

05:29
Nina Shah

Future Directions in Myeloma Post-ASCO Discussion

09:02
Maria-Victoria Mateos

FDA Approves Once-Weekly Carfilzomib Regimen for Myeloma

08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
11:57
2018 Pan Pacific Lymphoma Conference

Quadruplet Therapy in Myeloma, New Pembro Data and Relevance of Auto…

Feat. S. Holstein
17:58
City of Hope

Should Everyone Receive Monoclonal Antibodies at First Myeloma Relap…

Feat. J. Mikhael
15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How t…

Feat. S. Lonial
17:59
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Novel Agents, Antibodies, Targeted Therapies and Related Studies in …

Feat. T. Martin